Authors

Rethinking Market Access in CEE: Time to Bust the Myths

Challenging six misconceptions that have characterized product strategies in Central and Eastern European markets.

Your DSCSA Responsibilities

Discover essential guidelines for complying with the Drug Supply Chain Security Act (DSCSA). Learn how to enhance supply chain security and meet regulatory standards across various roles in the pharmaceutical industry.

Why Healthcare Costs are Surging—And What to Do About it

Identifying the inflators and deflators, and the role all stakeholders play.

The DTP Balance Sheet: Access Up, Friction Down

Third in a three-part series

Navigating a Formulary Loss: How One Brand Protected Market Share

This case study explores how one pharmaceutical brand responded to a significant formulary loss, implementing seamless provider prior authorization strategies through CoverMyMeds to mitigate impact and maintain market share in a highly competitive class.

ROI and Rare Disease: Retooling the ‘Gene’ Value Machine

Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.

Proactive Engagement: How AI-Driven Alerts are Transforming HCP Outreach

The benefits for brand teams in bolstering their rapid-response capability.

HEOR: From Proving Product Value to Proving Its Own Worth

The recent shift in Health Economics and Outcomes Research functions across major pharmaceutical companies highlights a lack of understanding of its value.

From Uncertainty to Opportunity: Navigating IPAY 2028

How the 2028 Medicare drug price negotiations will reshape market access, provider reimbursement, and patient care

Your Trusted Resource for Mission Critical Solutions

There’s a reason your facility’s most sensitive operations are called “mission critical.” Learn how ABM’s highly technical management services can take the worry out of maintaining your most specialized systems.

Introducing Agentic AI: Its Revolutionary Potential in Pharma

A look at the promise and opportunities from this new and advanced type of AI in transforming commercial planning and execution for life sciences companies.

AI Can’t Lead. Healthcare Needs Leaders

It’s the caliber of leadership that brings teams together, demands accountability, and drives purposeful, decisive action.

FDA’s New Accelerated Approval Draft Guidance

What biopharma companies need to know about this evolving regulatory pathway.

Why Healthcare Costs are Surging—And What to Do About it

Identifying the inflators and deflators, and the role all stakeholders play.

Site Satisfaction Is the New Competitive Advantage

Clinical trial sites face persistent payment delays and complex processes, risking their viability and impacting drug development. Solutions prioritize transparency and flexibility.

Engaging Patients: Why Pharma’s Direct-to-Patient Approach Should Be Applauded

Physicians remain central even as DTP programs are implemented.

Realtime Electronic Data Capture at Investigator Sites: Laboratory Data and Beyond

Beyond Awareness: Modeling Shared Decision-Making in Patient Communications

When patients struggle to see a positive path forward, modeling a constructive journey can give them the confidence they need.

Impact, Access, and Scale: The Potential of India’s Pharma Market

Country is poised to offer growth-channel opportunities for global pharma companies ready to scale access, innovation, and profitability.

AI in Drug Discovery On-Demand Webinar

Revolutionizing Pharma Patient Assistance Programs, KnippeRx Leads the Future of Patient Care

Impact, Access, and Scale: The Potential of India’s Pharma Market

Country is poised to offer growth-channel opportunities for global pharma companies ready to scale access, innovation, and profitability.

The Shifting Pharmacy Landscape in 2025

Polypharmacy, biosimilars, and GLP-1s among the evolving trends likely to play out in the pharmacy benefits space.

Going Beyond Compliance: Early Adoption of FDA’s Quality Management Maturity Program—and the Practical Considerations for Executives

An examination of proactive preparedness and readiness review for future enrollment in the agency’s QMM program—now in the pilot stage as an effort to incentivize pharma manufacturers to achieve a more mature state of quality culture.

Rethinking Audience Modeling: AI, Regulations, & More

The intersection of artificial intelligence and direct-to-consumer advertising presents unprecedented opportunities and evolving challenges as regulations and technologies reshape the biopharma landscape.

How AI is Shaping KOL and DOL Identification

As drugmakers navigate an increasingly complex terrain of scientific and digital influence, the ability to accurately identify and understand both key and digital opinion leaders is vital for effective engagement.

HEOR: From Proving Product Value to Proving Its Own Worth

The recent shift in Health Economics and Outcomes Research functions across major pharmaceutical companies highlights a lack of understanding of its value.

Beyond the Prescription: The Role Pharma Plays in Digital Health Conversations

As social media continues to influence healthcare communication, it presents both challenges and opportunities for the pharmaceutical industry. In this interview, Jennifer Harakal of Canopy Life Sciences discusses balancing compliance with effective digital engagement to build trust and facilitate meaningful healthcare conversations.

Beyond the Data: Making HCP Analytics Actually Work for Commercial Teams

Traditional approaches to HCP segmentation are no longer sufficient. The challenge now is to maintain personalization at scale while managing large territories and diverse customer bases.